PFIZER has decided not to go ahead with the listing of atopic dermatitis drug Cibinqo (abrocitinib) on the Pharmaceutical Benefits Scheme (PBS), citing economic considerations.
The listing was recommended by the Pharmaceutical Benefits Advisory Committee (PBAC) in Nov 2024, but Pfizer determined that the expected net price level and the current Risk Share Arrangement (RSA) would make the PBS listing commercially unsustainable for the company.
It also said the average selling price for Cibinqo "does not reflect the value of innovation", and while recognising that the RSA framework is intended to help limit government expenditure, it also limits patients' access to therapies.
"This decision represents a significant setback for consumers, patient advocacy groups, and healthcare professionals who continue to emphasise the critical need for more treatment options for those living with severe atopic dermatitis," said a Pfizer spokesperson.
"Australia must urgently create more flexible, patient-focused reimbursement that balances economic considerations with patient needs," they continued.
"Pfizer Australia joins industry, patients and healthcare professionals in calling for reform to Australia's Health Technology Assessment (HTA) to ensure patients can access the latest treatments when they need them."
The above article was sent to subscribers in Pharmacy Daily's issue from 02 Oct 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 02 Oct 25
